| Applications | Formulation / Composition |
Discovery | Preclinical | IND-Enabl. | Clinical | Projected Market Size (2030s, USD Billions) |
CAGR | |
|---|---|---|---|---|---|---|---|---|
|
Arteriovenous Fistulas (AVF) |
Gel, NO | 1.4 |
5.9% (2023-2033) |
|||||
| Coronary Stents | Coating, NO | 15.6 |
6.3% (2022-2030) |
|||||
| Flow Diverters | Coating, NO | 1.6 |
14.3% (2024-2034) |
|||||
|
Angioplasty Balloons |
Coating, Sirolimus+NO |
3.3 |
3.5% (2022-2027) |
|||||
|
Direct Pulp Capping |
Coating, NO | 3.8 |
5.9% (2023-2032) |
|||||
| Orthopedic Applications | Gel, NO | 14.5 |
5.1% (2024-2032) |
Arteriovenous fistulas (AVF) are vital for hemodialysis in patients with end-stage renal disease, enhancing vein blood flow to facilitate effective treatment.
The Bionanomatrix gel coats AVFs to accelerate maturation by promoting endothelial cell growth and reducing smooth muscle proliferation, crucial for minimizing AVF failure.
The gel is currently in preclinical trials, with a focus on optimizing its effectiveness for enhancing AVF longevity.
The AVF treatment market is poised to grow from USD 765.8 million in 2023 to USD 1.356 billion by 2033, driven by technological advances and robust government support, with the U.S. leading due to significant related healthcare costs.
The gel targets the 60% failure rate of AVFs by enhancing cell function and preventing complications, aiming to reduce hospitalizations and improve AVF durability for dialysis patients.
Source – Future Market Insights
Coronary stents are crucial in angioplasty, maintaining open blood vessels and reducing heart attack risks.
The Bionanomatrix coating promotes endothelial lining healing within blood vessels. It accelerates recovery, prevents blood clot formation, and reduces stent narrowing, overcoming issues typically seen with bare metal and drug-eluting stents.
In tests using a rabbit artery injury model over 28 days, Bionanomatrix-coated stents demonstrated complete endothelial recovery, reduced inflammation, and minimal neointimal hyperplasia, outperforming both bare metal and drug-eluting stents.
The coronary stents market is expected to hit USD 15.6 billion by 2030, with a 6.3% CAGR from 2022. Growth drivers include:
The Bionanomatrix coating significantly enhances coronary stents by ensuring complete endothelial recovery and reducing the risks of thrombosis and restenosis, thereby improving stent functionality and patient outcomes.
Source – Market Research Future
Flow diverters are critical for managing brain aneurysms by redirecting blood flow from the aneurysm via a metallic mesh structure, significantly reducing the risk of rupture through a minimally invasive procedure.
The Bionanomatrix coating on flow diverters boosts endothelialization and speeds up aneurysm closure, aiming to lessen the reliance on prolonged antiplatelet therapy by fostering faster healing and reducing thrombus formation.
The Bionanomatrix coating is being tested both in vitro and in vivo to confirm its effectiveness in promoting robust aneurysm occlusion and reducing the recurrence rates typical of conventional treatments.
The flow diverter market is projected to grow from USD 413.4 million in 2024 to USD 1,573.3 million by 2034 at a CAGR of 14.3% due to:
The Bionanomatrix coating on flow diverters significantly lowers treatment risks by reducing aneurysm recurrence and the need for retreatment. It enhances patient safety by accelerating occlusion and minimizing the duration of antiplatelet therapy, thereby decreasing the risks linked to long-term medication use.
Source – Future Market Insights
Angioplasty balloons, including drug-coated variants, are crucial for treating vascular stenosis and peripheral artery disease (PAD). These devices facilitate vessel dilation during minimally invasive procedures, offering a surgical alternative.
Endomimetics has engineered a dual-action coating for drug-coated balloons (DCBs) that merges anti-proliferative agents with re-endothelialization enhancers. This coating is designed to curb neointimal hyperplasia, the main cause of restenosis, and improve vascular healing in PAD patients.
The innovative dual-action coating is advancing the capabilities of angioplasty balloons, especially for treating complex vascular conditions like PAD and in-stent restenosis (ISR). The focus is on refining the delivery and effectiveness of therapeutic agents used during angioplasty.
Valued at USD 2,639.25 million in 2021, the angioplasty balloon market is projected to reach USD 3,343.12 million by 2027, growing at a CAGR of 3.5%. Growth is driven by:
The dual-action coating on the angioplasty balloons offers significant clinical improvements:
Source – ASDReports
DPC is a dental procedure aimed at preserving dental pulp exposed by caries or trauma by placing a bioactive material over it to promote healing and reparative dentin formation.
Endomimetics is developing a bioactive Direct Pulp Capping material with its Bionanomatrix technology to overcome limitations of conventional materials. The material is designed to induce mineralized barrier formation, provide antimicrobial and anti-inflammatory effects, and improve physical properties like seal integrity, pH control, and setting time.
The novel DPC material is under development, focusing on enhancing bioactivity and cost-effectiveness to surpass the performance and reliability of existing products.
The tooth filling materials market, valued at over USD 2 billion in 2022, is expected to reach USD 3.8 billion by 2032, growing at a CAGR of 5.9%. Growth drivers include:
The bioactive DPC material aims to enhance clinical outcomes by:
Source – Transparency Market Research
Orthopedic surgical procedures and implants—including joint replacements, osseointegrated limb prostheses, plates, screws, and spinal hardware—share common complications such as infection, inflammation, poor vascularization, fibrotic encapsulation, and impaired osseointegration, which can result in pain, device malfunction, implant failure, and costly revision surgeries.
Bionanomatrix Platform: Coating and Gel
Bionanomatrix™ is available as both a surface coating and an injectable gel for orthopedic use.
In coating form:
In gel form:
Mechanism of Action in Orthopedics
Overall, supports stable bone and soft‑tissue integration and aims to extend implant longevity and function.
The global orthopedic implants market was valued at approximately USD 47–50 billion in 2022 and is projected to reach around USD 73 billion by 2032, reflecting a CAGR of roughly 4.5%.
Reconstructive joint replacements represent more than one‑third of total orthopedic implant revenue and are expected to remain the largest segment through 2032, driven by aging populations, rising osteoarthritis and osteoporosis, and higher volumes of joint replacement procedures.
The knee segment alone accounts for roughly one‑fourth of the market and is projected to retain its dominance, while spine is expected to show the fastest growth due to increasing spinal disorders and expanded fusion indications.
Demand for advanced, infection‑resistant, and biologically active implants and coatings is growing, creating a strong need for platforms like Bionanomatrix that address infection, inflammation, and integration at the implant–tissue interface.
Preclinical studies show that Bionanomatrix‑treated implants reduce biofilm, inflammatory cytokines, and fibrotic tissue around implanted materials, supporting translation to orthopedic hardware and joint implants. Supported by NIH SBIR and state‑level grants, the platform is being optimized for coating stability, NO and drug‑release kinetics, and in vivo performance, with flexibility to fit different implant geometries and risk profiles. Across orthopedic indications, the BionanomatrixTM aims to lower implant‑associated infection, decrease chronic inflammation, and limit fibrotic encapsulation to reduce complications and revisions.
Source – Global Market Insights
